Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

New Data Supports Efficacy and Safety of Boehringer Ingelheim’s Cyltezo, a Humira Biosimilar

Related Content

PTAB Institutes Sarepta’s IPR

Update on Recent International Biosimilar Approvals

Regeneron Files BPCIA Complaint Against Sandoz Regarding Aflibercept Biosimilar

FDA Approves Moderna’s and Pfizer/BioNTech’s Updated COVID-19 Vaccines

FTC Comment on FDA Draft Guidance on Interchangeability

Del. Judge Connolly Says Preambles Are Limiting, Cites Alice in Wonderland, and Invites the Federal Circuit to Weigh In

EMA Accepts Marketing Authorization Application for Alvotech’s AVT06 (aflibercept)

Proposed BPCIA Reform Legislation Likely To Have Little Effect Even If Passed

Goodwin Named an LMG Life Sciences Life Cycle Firm for the Twelfth Consecutive Year

LMG Recognizes Goodwin Lawyers and Practices for Excellence in Life Sciences

Goodwin Releases Update to its Comprehensive Guide to Biosimilars Litigation and Regulation in the U.S.

Goodwin Named an LMG Life Sciences Life Cycle Firm for the Tenth Consecutive Year

Goodwin Adds Life Sciences and Healthcare Litigation Partner William Jackson

China's Patent Linkage System: Can Strategies that Work in the U.S. System Be Applied to China?

Goodwin Named An LMG Life Sciences Life Cycle Firm For The Ninth Consecutive Year

ACI's 11th Summit on Biosimilars & Innovator Biologics

Life Sciences

Hatch-Waxman, Biologics and Biosimilars Litigation